2cureX AB — Investor Relations & Filings

2cureX AB is a company specializing in functional precision oncology, dedicated to improving cancer treatment outcomes. The company develops and commercializes the IndiTreat® test, a CE-marked in vitro diagnostic (IVD) tool that predicts individual patient response to cancer therapies. The IndiTreat® technology uses 3D tumoroids, or micro-tumors, grown from a patient's own biopsy. These tumoroids are then tested against various cancer drugs to identify the most effective treatment option before it is administered to the patient. This approach provides oncologists with personalized data to guide therapy selection, with an initial focus on patients with advanced cancers like metastatic colorectal cancer. By directly measuring drug sensitivity, 2cureX aims to provide a higher level of precision in personalized medicine.